Table 2.

Ventilatory parameters of participants after three days of placebo versus acetazolamide treatment

	Able-Bodied		SCI
	Placebo	Acetazolamide	Placebo	Acetazolamide
Total CO2, mEq/L	29.3 ± 3.7	22.4 ± 2.6*	28.7 ± 2.6	22.7 ± 2.3*
V̇e, L/min	7957.2 ± 2271.6	9123.9 ± 3204.4	6589.0 ± 2373.9	7939.6 ± 3134.8
VT, L	522.1 ± 104.1	584.5 ± 158.2	501.1 ± 30.7	569.4 ± 164.4
FB, breaths/min	15.3 ± 3.2	15.5 ± 3.1	13.0 ± 2.8	13.8 ± 3.8
TI, s	1.8 ± 0.3	1.8 ± 0.3	2.0 ± 0.3	2.0 ± 0.5
TE, s	2.3 ± 0.6	2.3 ± 0.6	2.9 ± 0.6	2.7 ± 1.0
TTot, s	4.1 ± 0.9	4.0 ± 0.8	4.8 ± 0.9	4.7 ± 1.4
TI/TTot	0.4 ± 0.0	0.4 ± 0.1	0.4 ± 0.0	0.4 ± 0.1
$\text{P}\mathrm{\text{E}}{\mathrm{\text{T}}}_{\text{C}{\mathrm{\text{O}}}_2}$, mmHg	37.4 ± 3.0	32.1 ± 5.3	38.1 ± 7.0	33.9 ± 6.0
O2Sat, %	96.3 ± 1.0	97.7 ± 1.1	96.1 ± 3.2	97.2 ± 1.9

F_B, respiratory rate; O₂Sat, oxyhemoglobin saturation; P_ETCO₂, end tidal CO₂ partial pressure; T_E, expiratory duration; T_I, inspiratory duration; T_I/T_Tot, fractional inspiratory time; T_Tot, breath duration; V̇e, minute ventilation; V_T, tidal volume.

^*P < 0.05 vs. placebo using paired-samples t test.